Diversify Advisory Services LLC Invests $448,000 in AtriCure, Inc. $ATRC

Diversify Advisory Services LLC bought a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,993 shares of the medical device company’s stock, valued at approximately $448,000.

Other institutional investors and hedge funds have also modified their holdings of the company. AQR Capital Management LLC raised its stake in AtriCure by 1.0% in the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after purchasing an additional 837 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of AtriCure by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after purchasing an additional 1,230 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of AtriCure by 1.0% during the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after purchasing an additional 8,956 shares during the period. Jane Street Group LLC increased its holdings in shares of AtriCure by 658.3% during the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after purchasing an additional 87,553 shares during the period. Finally, Strs Ohio acquired a new stake in shares of AtriCure in the first quarter valued at approximately $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AtriCure

In other news, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the completion of the transaction, the director owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This represents a 38.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Justin J. Noznesky sold 6,182 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the transaction, the insider directly owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This represents a 5.81% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 44,246 shares of company stock valued at $1,691,895. 4.00% of the stock is currently owned by corporate insiders.

AtriCure Stock Down 0.3%

Shares of NASDAQ:ATRC opened at $47.49 on Friday. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $48.46. The company has a market capitalization of $2.42 billion, a PE ratio of 226.15 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a fifty day moving average of $35.42 and a 200-day moving average of $31.72.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter last year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts predict that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ATRC. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Raymond James Financial set a $52.00 target price on shares of AtriCure in a report on Tuesday, July 21st. UBS Group dropped their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Finally, Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.